June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Outcomes of corneal crosslinking for keratoconus in children and young adults
Author Affiliations & Notes
  • Solin Saleh
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Euna B Koo
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Scott R Lambert
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Edward E Manche
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Solin Saleh, None; Euna Koo, None; Scott Lambert, None; Edward Manche, Alcon, Inc. (F), Allergan, Inc. (F), Avedro, Inc. (C), Avedro, Inc. (F), Carl Zeiss Meditec (F), Johnson and Johnson Vision, Inc. (C), Johnson and Johnson Vision, Inc. (F), Placid0, Inc. (I), Presbia (F), RxSight, Inc. (I), VacuSite, Inc. (I)
  • Footnotes
    Support  NIH P30 EY026877
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 775. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Solin Saleh, Euna B Koo, Scott R Lambert, Edward E Manche; Outcomes of corneal crosslinking for keratoconus in children and young adults. Invest. Ophthalmol. Vis. Sci. 2021;62(8):775.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is limited North American data on the efficacy of corneal crosslinking for pediatric keratoconus, which is often severe at diagnosis and progresses rapidly. We performed a retrospective medical record review to assess the effect of corneal crosslinking on vision, keratometry and wavefront aberration in children and young adults with progressive keratoconus.

Methods : We included patients aged ≤ 22 years with keratoconus who underwent corneal crosslinking between January 2013 and November 2019 at Byers Eye Institute at Stanford University. Outcome measures included logMAR corrected distance visual acuity (CDVA), keratometry and total wavefront aberration. Measurements were taken at baseline and 12 and 24 months postoperatively.

Results : A total of 57 eyes of 49 patients aged 12-22 years were included. The mean preoperative CDVA was logMAR 0.38 ± 0.32 (20/48) and postoperative CDVAs were logMAR 0.29 ± 0.31 (20/39) and 0.31 ± 0.31 (20/41) at 12 and 24 months postoperatively. Compared to preoperative mean Kmax, there was an improvement of -0.8 D to a mean postoperative Kmax of 59.1 ± 9.1 D at 12 months and -1.3 D to 59.7 ± 8.8 D at 24 months. Linear mixed modelling showed significant improvements in Kmax at 12 and 24 months (p=0.013, p=0.001, respectively). In a sub-analysis of available wavefront aberration data, there were no significant changes in root mean square, defocus, astigmatism, coma, trefoil, tetrafoil, spherical aberration or second order astigmatism at 12 months postoperatively.

Conclusions : Corneal crosslinking stabilized, and in some cases improved the visual, topographic and wavefront aberration parameters in pediatric and young adult patients with keratoconus. The procedure may prevent disease progression in this population.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×